Our activities are focused on the development of original and generic drugs in the following therapeutic areas:
The company's products are developed by its own research and development arm, The Center of Immunology Engineering in Lyubuchany, near Chekhov, in the Moscow Region. Production of drugs is conducted at modern plant using "Good Manufacturing Practices" ( GMP, GOST R 52249-2009). The company produces its own active ingredients. BIOCAD is the leading domestic company according to the number of new clinical studies proving the effectiveness and safety of our medicines.
BIOCAD is developing modern methods of pharmacotherapy for patients with severe debilitating autoimmune diseases. Since 2005, the research division of the company is focused on high-tech development of generic and original medicines for the treatment of multiple sclerosis and rheumatoid arthritis. Interferon beta-1b (BIOCAD) is the first Russian biosimilar of recombinant human interferon beta-1b against multiple sclerosis that is provided to patients under the government program since 2010. The company not only supplies modern, effective and safe drugs, but also offers additional support programs, allowing patients to adapt quicker to therapy, and to make it more successful. For patients receiving Interferon beta-1b (BIOCAD), we implemented BETA life support program, in which each patient is provided with comfortable therapy tools, information and counseling.
Russia's first product of recombinant human interferon beta-1b, used to treat multiple sclerosis.